Search results for "coagulation"

showing 10 items of 381 documents

Hemorrhage in patients under oral anticoagulation for atrial fibrillation. The other side of the coin

2019

Abstract Introduction and objectives Oral anticoagulation therapy is prescribed to most patients with atrial fibrillation. The main limitation of anticoagulant treatment is the occurrence of bleeding episodes. We sought to assess the type of hemorrhages and mortality in patients anticoagulated for nonvalvular atrial fibrillation. Methods Observational retrospective study analyzing 2 081 138 hospitalization reports from 2014 corresponding to 151 hospitals of the Spanish National Health System. Patients were selected with the diagnosis of hemorrhage, nonvalvular atrial fibrillation, and oral anticoagulation. Results A total of 5783 hospitalizations were analyzed. Most hemorrhages were digesti…

National healthmedicine.medical_specialtyBleeding episodeseducation.field_of_studybusiness.industryPopulationRetrospective cohort studyAtrial fibrillationmedicine.diseaseAnticoagulant therapyInternal medicinemedicineIn patientCardiology and Cardiovascular MedicineeducationbusinessOral anticoagulationREC: CardioClinics
researchProduct

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ER…

2020

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

ORAL ANTICOAGULANT-THERAPYdiagnosis[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematologyEmbolectomyGuidelineRECURRENT VENOUS THROMBOEMBOLISM0302 clinical medicinePregnancyDaily practiceDiagnosisPulmonary medicineVenous thrombosisPulmonary MedicineThrombolytic TherapyDEEP-VEIN THROMBOSISDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUShealth care economics and organizationsRisk assessmentddc:616RIGHT-VENTRICULAR DYSFUNCTIONDisease ManagementShockMOLECULAR-WEIGHT HEPARINThrombolysishumanities3. Good healthPulmonary embolismEuropeAnticoagulation; Biomarkers; Diagnosis; Dyspnoea; Echocardiography; Embolectomy; Guidelines; Heart failure; Pregnancy; Pulmonary embolism; Right ventricle; Risk assessment; Shock; Thrombolysis; Treatment; Venous thromboembolism; Venous thrombosismedicine.veinEchocardiographyAcute DiseaseRight ventricleMedical emergencyCardiology and Cardiovascular MedicineRisk assessmentguidelines; pulmonary embolism; venous thrombosis; shock dyspnoea; heart failure: right ventricle: diagnosis; risk assessment: echocardiography; biomarkers; treatment; anticoagulation; thrombolysis; pregnancy; venous thromboembolism; embolectomyDiagnosiVenous thromboembolismthrombolysiseducationCardiologyMEDLINEThrombolysiHeart failure610 Medicine & healthGuidelinesInferior vena cava2705 Cardiology and Cardiovascular MedicineEXTRACORPOREAL MEMBRANE-OXYGENATION03 medical and health sciencesAnticoagulationMedicalDyspnoeamedicineHumansRIGHT HEART THROMBIVENTILATION-PERFUSION SCINTIGRAPHYshock dyspnoeaHealth professionalsbusiness.industryINFERIOR VENA-CAVA10031 Clinic for Angiologyheart failure: right ventricle: diagnosisPulmonary embolismAnticoagulantsbiomarkersrisk assessment: echocardiography030229 sport sciencesBiomarkermedicine.diseaseTreatmentINHALED NITRIC-OXIDESocietiesbusinessBiomarkers
researchProduct

Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.

2017

The diagnosis of essential thrombocythemia and polycythemia vera is often made during a thrombotic event which can be serious. Philadelphia-negative chronic myeloproliferative neoplasia patients have an increased thrombotic risk. This is assessed using various scoring systems but these are far from ideal and individual risk. The currend trend to personalised medicine requires finding the most useful thrombotic risk biomarker in these patients. Routine tests for coagulation do not take account of both pro- and anti-coagulant factors which is why these tests are not useful in patients with Philadelphia-negative myeloproliferative neoplasms. Thrombin generation reflects more accurately the bal…

OncologyBlood PlateletsPathologymedicine.medical_specialtylcsh:Medicinemyeloproliferative neoplasmsGeneral Biochemistry Genetics and Molecular BiologyLeukemia Myeloid Chronic Atypical BCR-ABL NegativeDiagnosis Differential03 medical and health sciences0302 clinical medicinePolycythemia verapolycythemia veraCell-Derived MicroparticlesRisk Factorshemic and lymphatic diseasesInternal medicinemedicineBiomarkers TumorHumansThrombophiliaPlateletjak2 v617fMyeloproliferative neoplasmessential thrombocythemiaEssential thrombocythemiabusiness.industrylcsh:RThrombinThrombosispersonalized medicineJanus Kinase 2medicine.diseaseThrombosisCoagulationthrombin generation030220 oncology & carcinogenesisplateletsBiomarker (medicine)Personalized medicinebusinessthrombotic risk030215 immunologyBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
researchProduct

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Mali…

2021

Immune checkpoint inhibitors (ICI) significantly improved the prognosis of advanced melanoma patients. However, many patients do not derive long-term benefit from ICI therapy due to primary and acquired resistance. In this regard, it has been shown that coagulation factors contribute to cancer immune evasion and might therefore promote resistance to ICI. In particular, recent observations in murine systems demonstrated that myeloid-derived factor Xa (FXa) impedes anti-tumor immunity in the tumor microenvironment and that the oral FXa inhibitor (FXa-i) rivaroxaban synergizes with ICI. The synergistic effect of FXa inhibitors with clinical ICI therapy is unknown. We performed a retrospective …

Oncologyadvanced melanomaCancer Researchmedicine.medical_specialtymedicine.drug_mechanism_of_actionmedicine.medical_treatmentFactor Xa Inhibitorfactor Xa inhibitorsanti-tumor immunityArticleimmune checkpoint inhibitorsInternal medicinemedicineProgression-free survivalanticoagulationRC254-282thromboembolic eventsRivaroxabanbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerRetrospective cohort studyImmunotherapymedicine.diseaseOncologyConcomitantimmunotherapythromboprophylaxisbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCohort studyCancers
researchProduct

Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets

2019

Platelet-dependent thrombin generation is a helpful tool to assess ex vivo the interaction between platelets and plasma coagulation factors in the initiation, amplification, and inhibition of thrombin generation (TG). This review article discusses the most relevant available data on the clinical applications of fluorogenic TG, the most widely used TG assay, performed in the presence of platelets, i.e., in platelet-rich plasma. With respect to prothrombotic states, arterial hypertension and obesity were the most prominent cardiovascular conditions linked to increased platelet-dependent TG. In addition, platelet-associated hypercoagulability, assessed by the TG assay, has been shown in indivi…

Oncologycardiovascular risk factorsmedicine.medical_specialtyBLEEDING PHENOTYPElcsh:MedicineReview030204 cardiovascular system & hematologyHYPERCOAGULABILITYACTIVATION03 medical and health sciences0302 clinical medicineInternal medicinehemophiliamedicineVon Willebrand diseasePlateletSEVERE HEMOPHILIA-AthrombosisVENOUS THROMBOEMBOLISMRICH PLASMAbiologybusiness.industryCALIBRATED AUTOMATED THROMBOGRAMlcsh:RRECOMBINANT FACTOR VIIAGeneral Medicinemedicine.diseasebleedingThrombosisFACTOR-V DEFICIENCYcardiovascular diseasesBleeding diathesisCoagulationRecombinant factor VIIathrombin generationOBESITYplateletsbiology.proteinBiomarker (medicine)businessvon Willebrand diseaseEx vivo030215 immunologyJournal of Clinical Medicine
researchProduct

State-of-the-Art Review : Chemotherapy and Thrombosis in Gynecologic Malignancy

1999

Thromboembolism is a severe and frequent problem in gynecologic malignancy. The average DVT incidence during chemotherapy of 5% might represent the lower range of incidence because < 55% of thrombotic complication manifest clinical signs. However, it seems likely that in addition to chemotherapy other risk factors such as menopausal status, BMI of patients, or type of preceding surgery must coincide before thrombosis manifests. While monitoring of patients using sophisticated coagulation tests did not identify patients' risk for DVT during chemotherapy, an evaluation of the coagulation status before initiating chemotherapy is recommended. Patients with a venous access device (e.g., indwelli…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentIncidence (epidemiology)HematologyGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseThrombosis03 medical and health sciencesGynecologic malignancy0302 clinical medicinePort (medical)030220 oncology & carcinogenesisInternal medicinemedicineCoagulation testingcardiovascular diseasesbusinessCentral venous catheterThrombosis preventionClinical and Applied Thrombosis/Hemostasis
researchProduct

Pseudoxanthoma elasticum‐like syndrome with coagulation deficiency associated with carotid artery hypoplasia and a novel gamma‐glutamyl carboxylase g…

2020

Pathologymedicine.medical_specialtyCarboxy-Lyasesbusiness.industryCarotid arteriesPseudoxanthoma elasticum-like syndromeDermatologyGene mutationmedicine.diseaseHypoplasiaGamma-glutamyl carboxylaseCarotid ArteriesCarbon-Carbon LigasesCoagulationMutationmedicineHumansPseudoxanthoma ElasticumbusinessInternational Journal of Dermatology
researchProduct

A case of Waldenstroem's disease with a monoclonal IgM antiphospholipid antibody

2002

The antiphospholipid syndrome (APS) was described in 1983 as a clinical entity characterized by venous and arterial thrombosis, thrombocytopenia, and recurrent fetal loss. The serological markers of APS are antiphospholipid antibodies (APLA) directed mainly against anionic phospholipids, usually cardiolipin but also phosphatidylserine. Some APLA exhibit lupus anticoagulant activity. Monoclonal gammopathy sometimes occurs with the presence of autoantibodies. In this paper, we describe a patient with the diagnosis of immunocytoma with an IgM, kappa paraprotein with apparent specificity against anionic phospholipids, and lupus anticoagulant activity, but no clinical signs of APS. We describe i…

Pathologymedicine.medical_specialtyImmunologymedicine.disease_causeSerologyAutoimmunityImmunoglobulin kappa-ChainsRheumatologyimmune system diseasesAntiphospholipid syndromemedicineHumansImmunology and AllergyGlycoproteinsLupus anticoagulantbiologybusiness.industryAutoantibodyWaldenstrom macroglobulinemiaMiddle Agedmedicine.diseaseTreatment OutcomeImmunoglobulin Mbeta 2-Glycoprotein ILupus Coagulation InhibitorImmunologyMonoclonalAntibodies Antiphospholipidbiology.proteinFemaleWaldenstrom MacroglobulinemiaAntibodybusinessParaproteinsRheumatology International
researchProduct

Neonatal form of nemaline myopathy, muscle immaturity, and a microvascular injury.

1990

An infant with a neonatal form of nemaline myopathy showed ultrastructural features of muscle immaturity. Immaturity was characterized by an abnormal presence of myotubes, as well as cells in clusters within a common basement membrane and a great number of satellite cells adhering to very small muscle fibers. In addition, degenerative changes and a severe microvascular lesion were observed. The pathologic findings in the muscle of this patient were those of neonatal nemaline myopathy complicating severe microvascular injury, possibly induced by an unknown toxic agent. ( J Child Neurol 1990;5:122-126).

Pathologymedicine.medical_specialtyMuscle HypotoniaBiopsyIschemiaBiologyMuscle Smooth VascularLesion03 medical and health sciences0302 clinical medicineNemaline myopathyMyofibrilsIschemia030225 pediatricsBiopsymedicineHumansBasement membraneInclusion BodiesAsphyxia NeonatorumRespiratory Distress Syndrome Newbornmedicine.diagnostic_testMyogenesisMicrocirculationMusclesInfant NewbornDisseminated Intravascular Coagulationmedicine.diseaseMicroscopy ElectronMuscular Atrophymedicine.anatomical_structurePediatrics Perinatology and Child HealthMuscle HypotoniaFemaleNeurology (clinical)medicine.symptomMyofibril030217 neurology & neurosurgeryJournal of child neurology
researchProduct

Effects of laser-induced thermotherapy (LITT) on proliferation and apoptosis of glioma cells in rat brain transplantation tumors.

2002

Background and Objectives Laser-induced thermotherapy (LITT) is an approach to the treatment of brain tumors especially in poorly accessible regions. Its clinical applicability with tumor cell destruction has been shown in several studies. However, no data are known about specific effects on tumors cells due to LITT in the time course of the lesion. Study Design/Materials and Methods LITT was performed in adult Lewis rats with implanted glioma cells in the brain using a standard exposure of 3 W for 30 seconds. Before and following LITT, neoplastic lesions were monitored by MRI. Proliferation of implanted cells and gliosis were assessed by several histological techniques and immunohistochemi…

Pathologymedicine.medical_specialtyNecrosisLaser-induced thermotherapyApoptosisDermatologyLesionNecrosisGliomaIn Situ Nick-End LabelingMedicineAnimalsLaser Coagulationbusiness.industryBrain NeoplasmsGliomamedicine.diseaseMagnetic Resonance ImagingSurvival AnalysisRatsTransplantationTreatment OutcomeGliosisApoptosisRats Inbred LewImmunohistochemistrySurgerymedicine.symptombusinessCell DivisionNeoplasm TransplantationLasers in surgery and medicine
researchProduct